Necrostatin-1

Name: Necrostatin-1
Brand: Selleck Chemicals
SKU: S8037
Rating: 5 (52 reviews)

For research use only.

Catalog No.S8037

52 publications

Molecular Weight(MW): 259.33

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.

Selleck's Necrostatin-1 has been cited by 52 publications

Sci Adv, 2020, 25;6(13):eaay9789

PubMed: 32232155 ( click the link to review the publication )

Cell Death Dis, 2020, 22;11(5):391

PubMed: 32444644 ( click the link to review the publication )

Mol Nutr Food Res, 2020, 1;e1901231

PubMed: 32476238 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 4;2020:5021983

PubMed: 32322335 ( click the link to review the publication )

J Biol Chem, 2020, 1;295(18):6236-6248

PubMed: 32179652 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0376-8

PubMed: 32132657 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 8;521(2):414-419

PubMed: 31672277 ( click the link to review the publication )

Med Sci Monit, 2020, 26:e919739

PubMed: 32019905 ( click the link to review the publication )

Biosci Biotechnol Biochem, 2020, 18;1-8

PubMed: 32419644 ( click the link to review the publication )

Sci Total Environ, 2020, 699:134296

PubMed: 31683218 ( click the link to review the publication )

Cell Rep, 2020, 30(1):25-36

PubMed: 31914391 ( click the link to review the publication )

Int J Oncol, 2020, 56(2):439-447

PubMed: 31894265 ( click the link to review the publication )

J Clin Invest, 2019, 129(6):2431-2445

PubMed: 31081803 ( click the link to review the publication )

EMBO Rep, 2019, 20(10):e47840

PubMed: 31410978 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0274-0

PubMed: 30760873 ( click the link to review the publication )

Front Oncol, 2019, 9:436

PubMed: 31192135 ( click the link to review the publication )

J Biol Chem, 2019, 10.1074/jbc.RA119.010379

PubMed: 31723031 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6678-6690

PubMed: 31803362 ( click the link to review the publication )

J Hepatol, 2018, 68(6):1228-1238

PubMed: 29408314 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1680

PubMed: 29700283 ( click the link to review the publication )

Autophagy, 2018, 14(5):778-795

PubMed: 29171784 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Oncogene, 2018, 37(29):4033-4045

PubMed: 29706658 ( click the link to review the publication )
Oncoimmunology, 2018, 7(6):e1431086

PubMed: 29872558 ( click the link to review the publication )

Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1514-1527

PubMed: 30210920 ( click the link to review the publication )

Ann Biomed Eng, 2018, 46(7):1013-1025

PubMed: 29603044 ( click the link to review the publication )

Toxicology, 2018, 406-407:33-43

PubMed: 29860048 ( click the link to review the publication )

Am J Transl Res, 2018, 10(5):1357-1372

PubMed: 29887951 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):3051-3062

PubMed: 29436589 ( click the link to review the publication )

Int J Med Sci, 2018, 15(14):1648-1657

PubMed: 30588188 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):43

PubMed: 29970185 ( click the link to review the publication )

Cancer Lett, 2017, 381(1):96-103

PubMed: 27477897 ( click the link to review the publication )

Cancer Lett, 2017, 402:81-92

PubMed: 28576750 ( click the link to review the publication )

Cell Cycle, 2017, 16(4):348-359

PubMed: 27929749 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(4):659-70

PubMed: 27050456 ( click the link to review the publication )

Autophagy, 2016, 12(10):1738-1758

PubMed: 27463126 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0523

PubMed: 27302164 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 8;35(1):192

PubMed: 27931237 ( click the link to review the publication )

Free Radical Biology and Medicine, 2016, S0891-5849(16)00114-3

PubMed: 27012422 ( click the link to review the publication )

Sci Rep, 2016, 6:24245

PubMed: 27095146 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):1135-42

PubMed: 27349281 ( click the link to review the publication )

Mutat Res, 2016, 789:1-8

PubMed: 27155559 ( click the link to review the publication )

Genet Mol Res, 2016, 10.4238/gmr.15027298

PubMed: 27323061 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2199

PubMed: 25724678 ( click the link to review the publication )
J Cell Mol Med, 2015, 10.1111/jcmm.12495

PubMed: 25754842 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134144

PubMed: 26270345 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0122083

PubMed: 25894744 ( click the link to review the publication )

Oncotarget, 2015, 6(15):13476-86

PubMed: 25974963 ( click the link to review the publication )

Purity & Quality Control

Choose Selective TNF-alpha Inhibitors

Biological Activity

Description

Features

A powerful tool for characterizing the role of necroptosis with characterized primary target.

Targets

RIP1 ^[1]
(293T cells)

490 nM(EC50)

In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. ^[1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MkXUOVDDqM7:TR?=	MWOyOOKhcA>?		NV3BS3dNcW6qaXLpeJMhVU2VLXnu[JVk\WRiY3XscEBl\WG2aB?=	NXnQeVBlOjZ2N{K3NlM>
MEFs	NYHaWJQ3S2WubDDWbYFjcWyrdImgRZN{[Xl?	Mn71NVDjiIoQvF2=	MoPwOFghcA>?	NVTScZlETE2VTx?=	NU\ZNYZpcW6qaXLpeJMhgl[DRD3wdo9ud3SnZDDk[YF1cCCxZjDDUm9VOy2mZYDs[ZRm\CCPRV\z	MYCyOlQ{Pzd6OR?=
BMDM	M4HHd2Z2dmO2aX;uJGF{e2G7	M3X3VVExyqEQvF2=	NFXFfFY{OMLibXnu		M2fDfpBzd3SnY4TzJINmdGy\|IH\yc40hXEGNST3pcoR2[2WmIFzETEBz\WynYYPl	NU\uU2ttOjZ\|OEG2NFE>
NCI-H28	MmL5R4VtdCCYaXHibYxqfHliQYPzZZk>	MXyxNOKh\|ryP	NHzDfWQzPMLiaB?=		Mnr6dJJmfmWwdIOgSGFRTS2rbnT1Z4VlKHKnZIXjeIlwdiCxZjDOR2kuUDJ6IHPlcIwhfmmjYnnsbZR6yqB?	MlLGNlYxODRzM{i=
MiaPaCa-2	NYiwSlZnTnWwY4Tpc44hSXO\|YYm=	MlLINlAh\|ryP	NH7ZOGEzPCCq		M4LFbYRm[3KnYYPld{B1cGViZXHycJkhdmWlcn;0bYMh[2WubIO=	MXWyOlAxODZyNx?=
BxPC-3	MV\GeY5kfGmxbjDBd5NigQ>?	NWLxRnV[OjBizszN	MkPPNlQhcA>?		NH24eVRl\WO{ZXHz[ZMhfGinIHXhdox6KG6nY4LveIlkKGOnbHzz	M1XDVVI3ODByNkC3
SGC-7901	NEGwSZlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NYLXN5FUOzEEoN88US=>	M4P1WlHDqGh?		MoTxd5VxeHKnc4Pld{BwgGGuaYDsZZRqdi2vZXTpZZRm\CClZXzsJIRm[XSq	NYXrdZR{OjV5NkewO\|Y>
KMS-12-PE	NHzLOJRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXm2NEDPxE1?	MV[1JIg>		NF3pd\|VqdmirYnn0d{BUUEtvaX7keYNm\CClZXzsJIRm[XSq	MmfrNlU2OzByOUi=
L929-A	NVr2SXpSS2WubDDWbYFjcWyrdImgRZN{[Xl?	NGC0bHg2OMLizszNxsA>	MXmyOEBp		M1XBVoJtd2OtczDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh?	MnrGNlU{QTh3NEC=
L929-N	NXTvOmplS2WubDDWbYFjcWyrdImgRZN{[Xl?	M3zRTFUxyqEQvF5CpC=>	NY\M[ndQOjRiaB?=		Ml3IZoxw[2u\|IGTOSu6yNWmwZIXj[YQh[2WubDDk[YF1cA>?	M3;xTFI2Ozl6NUSw
L929-A	MX;GeY5kfGmxbjDBd5NigQ>?	MnnJOVDDqM7:TdMg	MW[xNkBp		NHPGbodjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?=	M4TYW\|I2Ozl6NUSw
L929-N	NXTSSoNkTnWwY4Tpc44hSXO\|YYm=	MkXSOVDDqM7:TdMg	NXXpdIZZOTJiaB?=		NH[zb3JjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?=	MV2yOVM6QDV2MB?=
L929	NF\oXlZHfW6ldHnvckBCe3OjeR?=	Mn;aOVDDqM7:TdMg	NGrZ[48yOiCq		NHq1PGVqdmirYnn0d{BVVkcQsT3pcoR2[2WmIFLp[EBkdGWjdnHn[S=>	MVeyOVM6QDV2MB?=
L929-A	NVTUZ2hOTnWwY4Tpc44hSXO\|YYm=	NUHEd\|J[PTEEoN88UeKh	NYK3fJVlOTJiaB?=		MWHpcohq[mm2czD0bIUhXE6IzsGtbY5lfWOnZDDsc5N{KG:oIH3peI9kcG:wZILpZYwhdWWvYoLhcoUheGW{bXXhZoltcXS7	MXyyOVM6QDV2MB?=
L929	MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXfme2ZrOzEEoN88US=>	MlztNeKhcA>?		M3u0R4lvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk>	MnHoNlUxQTV5NEK=
L929	M4HPbWNmdGxiVnnhZoltcXS7IFHzd4F6	NGnsRW0{OMLizszN	NW[5WJFJOcLiaB?=		NE\MbHRqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDjcIVifmGpZTDv[kBVd3CxIFm=	MVqyOVA6PTd2Mh?=
Huh7	MnXNR4VtdCCYaXHibYxqfHliQYPzZZk>	M3K5WFUxKML3TR?=	MmHXNlQwPDhiaB?=	MoD4SG1UVw>?	NXvNdnNOeHKndnXueJMh[2WubDDk[YF1cCCxZjDyRYRJS1ZiY3:tbY5n\WO2ZXSgTJVpPyClZXzsdy=>	NHnqOXgzPDl5M{K0NC=>
OHC	M1fEdWZ2dmO2aX;uJGF{e2G7	NYDOe\|RbOzBy4pEJ{txO		NXPleJJITE2VTx?=	MlTvbY5kemWjc3XzJI5wcXOnLXnu[JVk\WRiY3;u[IVve2WmIH71Z4xmcQ>?	NFLLelczPDh5NEezOC=>
OHC	M4nYbGZ2dmO2aX;uJGF{e2G7	NX7TV3U5OzBy4pEJ{txO		NVnSWVc4TE2VTx?=	MYjk[YNz\WG\|ZYOgco9qe2VvaX7keYNm\CC\|d3;scIVvKG63Y3zlbeKh	Mme2NlQ5PzR5M{S=
OHC	NX\vVnVMTnWwY4Tpc44hSXO\|YYm=	M1PBUVMxOOLCid88US=>		M{[3Z2ROW09?	MoKzdoV{fWy2czDpckBiKHKnZIXjeIlwdiCxZjDuc4l{\S2rbnT1Z4VlKFKLUEGgZY5lKFKLUEOgbY1ufW6xZnz1c5Jme2OnbnPl	MnSwNlQ5PzR5M{S=
OHC	M2nqVmZ2dmO2aX;uJGF{e2G7	MkXLN\|Ax6oDLzszN		Mo\6SG1UVw>?	MWfkbY1qdmm\|aHXzJI5wcXOnLXnu[JVk\WRiQV3QT{Bi[3SrdnH0bY9v	NWL4clF[OjR6N{S3N\|Q>
OHC	MYHGeY5kfGmxbjDBd5NigQ>?	NHz6NXQ{ODEkgJpOwG0>		M2TOc2ROW09?	M1H3VYlv[3KnYYPld{B1cGViboXtZoVzKG:oIHHwc5B1d3SrYzDPTGN{KHerdHjveZQh[Wy2ZYLpcochfGinIHzleoVteyCxZjDDR\|gh[W[2ZYKgco9qe2ViZYjwc5N2emV?	MVGyOFg4PDd\|NB?=
SK-Hep1	Mn\vSpVv[3Srb36gRZN{[Xl?	NIG2W4Q3OOLCid88UeKh	M2LJNVE56oDLaB?=		MmPFZoxw[2u\|wrFOtk1t[XCjY3jvcoUucW6mdXPl[EBud3KyaH;sc4dq[2GuIHPoZY5o\SxiY3XscEBl\WG2aDDhcoQhWElidYD0ZYtm	MWKyOFg{OjZyMh?=
SK-Hep1	NXzPe2JyTnWwY4Tpc44hSXO\|YYm=	MYm2NQKBkc7:TdMg	NIewXmEyQOLCiXi=		MmDybY5pcWKrdIOg{tIuVGGyYXPoc45mNWmwZIXj[YQhdGWja3Hn[UBw\iCKTVfCMVHDqA>?	MV2yOFg{OjZyMh?=
SK-Hep1	NGTyRnVHfW6ldHnvckBCe3OjeR?=	Moj2OlDjiIoQvF5CpC=>	MoHmNVjjiImq		M3nlPYJtd2Otc9Mg{tIudGGyYXPoc45mNW2nZHnheIVlKFCDUjDhZ4N2dXWuYYTpc44h[W6mIFHJSkB1emGwc3zvZ4F1cW:wIITvJJRp\SCleYTvd49tyqB?	M{fLcVI1QDN{NkCy
L-540	NEHMWIZHfW6ldHnvckBCe3OjeR?=	Ml3ROlDjiIoQvH2=	NETvc2Uy6oDLaB?=		MWLwdoV3\W62czD0bIUh\2WwZYLheIlwdiCxZjDSU3M>	NXmxb25qOjR3NkG1NVk>
L-540	MmXQSpVv[3Srb36gRZN{[Xl?	MYi2NQKBkc7:bR?=	M3Pxc\|HjiImq		NV33PYZ7eHKndnXueJMhfGinIH3peI9kcG:wZILpZYwhdWWvYoLhcoUh\GWyb3zhdol7[XSrb36=	NXf0N2FFOjR3NkG1NVk>
L-540	M2XnS2NmdGxiVnnhZoltcXS7IFHzd4F6	M37mb\|Yx6oDLzszt	MnPSNgKBkWh?		NE\KOYVz\WS3Y3XzJJRp\SCJaY\pco9{fGG2L2PvdoFn\W6rYj3pcoR2[2WmIHPlcIwh\GWjdHi=	M4fGNVI1PTZzNUG5
AGS	MmPtR4VtdCCYaXHibYxqfHliQYPzZZk>	MnvKOlDjiIoQvH2=	NHrHXmwy6oDLaB?=		NFvJ[HNxemW4ZX70d{B{cGmtb37pck1qdmS3Y3XkJINmdGxiZHXheIg>	Mlr3NlQ1PjNzOUm=
NRK-52E	MlfkR4VtdCCYaXHibYxqfHliQYPzZZk>	NIrMPJYzOCEQvF2=	MXiyOEBp		MVnwdo91\WO2czDj[YxteyCocn;tJINmdGxiZHXheIgh[2G3c3XkJIJ6KGm\|Y3jlcYliKGmwaoXyfS=>	NGDDZVEzPDN3MUi0OS=>
NRK-52E	MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2LWc\|IxKM7:TR?=	M2qzcVI1KGh?		NYDmS2d[cW6lcnXhd4V{KGOnbHygeoli[mmuaYT5JIFnfGW{IGTOSk3PuSCVdHnteYxifGmxbjDhcoQhSVSSIFTldIxmfGmxbh?=	MknENlQ{PTF6NEW=
NRK-52E	MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M3\ZUVIxKM7:TR?=	NWq2UIJOOjRiaB?=		Mmi0bY5pcWKrdIOgbY5kemWjc3XkJGRzeDFicILveIVqdiCneIDy[ZN{cW:wIHHmeIVzKFSQRj5OtUBUfGmvdXzheIlwdiCjbnSgRXRRKESncHzleIlwdg>?	MmXBNlQ{PTF6NEW=
L929	NI\5RZZHfW6ldHnvckBCe3OjeR?=	Ml[2Nk82yqEQvHevcYzDqA>?	M3jjdVI1yqCq		NVfCSmtVemW4ZYLz[YQhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG\|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ>	MX2yN\|k1OTd4OR?=
L929	M{XIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1m1NVIwPcLizsznM41tyqB?	M4nMblI1yqCq		MlvjdoV3\XK\|ZYOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZY5lKGOnbHyg[IVifGhiaX7keYNm\CCkeTDUUmbPuSCjbH;u[UBieyC5ZXzsJIF{KFSQRt8xxsAsyqC8VlHE	M4T0RVI{QTRzN{[5
L929	NHe0T45HfW6ldHnvckBCe3OjeR?=	MWiyxsDPxGdxbX\|CpC=>	NEXFZVgzPMLiaB?=		NF7xZXJxem:vb4TzJINie3Cjc3WtOkApeDJyKTDhZ5Rqfmm2eTDhcoQheHKxY3HzdIF{\S14IHPs[YF3[Wen	MVOyN\|k1OTd4OR?=
L929	M1flb2Z2dmO2aX;uJGF{e2G7	NV25V2R4PcLizsznM41t	M2\6[\|I1yqCq		M3rBZYJtd2OtczD6WmFFKGmwZIXj[YQhdmWlcn;weI9{cXNiYX7kJIF2fG:yaHHnfS=>	MoHkNlM6PDF5Nkm=
C6	M4WwVmNmdGxiVnnhZoltcXS7IFHzd4F6	NX\HZYx6OSCvbX;sM2w>	MkDjN{Bp		NXHHTlRY[XS2ZX71ZZRmeyCVaHnrc45qdiCrbnT1Z4VlKGeuaX;tZUBk\WyuIHTlZZRp	MlzaNlM5PDB2NEG=
U87	M2LZcWNmdGxiVnnhZoltcXS7IFHzd4F6	M4LER\|EhdW2xbD;M	MUKzJIg>		M2XjXoF1fGWwdXH0[ZMhW2ira3;ubY4hcW6mdXPl[EBodGmxbXGgZ4VtdCCmZXH0bC=>	MkSwNlM5PDB2NEG=
C6	NWDSem9{S3m2b4TvfIlkcXS7IFHzd4F6	M3HnSFEhdW2xbD;M	NIrseY4{KGh?		NXPPb29C[myxY3vzJJNpcWuxbnnuJIlv\HWlZXSgcoVkem:\|aYO=	NFy5NoIzOzh2MES0NS=>
U87	M4fITGN6fG:2b4jpZ4l1gSCDc4PhfS=>	M2DXZlEhdW2xbD;M	NV;vVYpJOyCq		MYricI9kc3Nic3jpb49vcW5iaX7keYNm\CCwZXPyc5Nqew>?	NYPQdmMxOjN6NEC0OFE>
C6	M3SyRWZ2dmO2aX;uJGF{e2G7	NUHuSmt3OSCvbX;sM2w>	NHrYR\|IyNjVvMzDo		MmPWd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBTUVBvMTDjZZV{\WRiYomgd4hqc2:waX6=	NF7PZVkzOzh2MES0NS=>
U87	MmXRSpVv[3Srb36gRZN{[Xl?	MlfJNUBudW:uL1y=	MkXlNU42NTNiaB?=		NFqwR\|h{fXCycnXzd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKFKLUD2xJINifXOnZDDifUB{cGmtb37pci=>	NYLjVHY{OjN6NEC0OFE>
TE671	MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Ml;GOFDjiIoQvHevcYzDqA>?	Mn;tNlQhcA>?		NUfOd2ljemW\|Y4Xld{BIYDF3LUC3NE1qdmS3Y3XkJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHl?	M2fRb\|I{PzR2Mkm2
RMS13	NXPNXIhrS2WubDDWbYFjcWyrdImgRZN{[Xl?	MlXVOFDjiIoQvHevcYzDqA>?	MUiyOEBp		M161SZJme2O3ZYOgS3gyPS1yN{CtbY5lfWOnZDDsc5N{KG:oIHPlcIwhfmmjYnnsbZR6	NYntO3Q4OjN5NESyPVY>
MEFs	NWXrNXZIS3m2b4TvfIlkcXS7IFHzd4F6	NVrzPFZxOi94L{KwJO69VQ>?	MmPvNVghcA>?		NGHneWJqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHigbY4hWmWuQTDLU{BOTU[\|	MlyzNlM4Ojd3OEG=
MEFs	MmnnSpVv[3Srb36gRZN{[Xl?	M2rzb\|IxyqEQvF2=	NY[xWFhCOS9{L{SgbC=>		M1Xnc5N2eHC{ZYPz[ZMhXE6IzsGtbY5lfWOnZDDSTXBMOSCyaH;zdIhwenmuYYTpc44>	MWKyN\|czPzV6MR?=
ΔN-Karpas 299	NHG3WYJEgXSxdH;4bYNqfHliQYPzZZk>	MmHzNlDDqM7:TR?=	MVSxOkBp		Mn2wbY5pcWKrdIOgR2Q{OC2rbnT1Z4VlKGOnbHyg[IVifGh?	MlO5NlM2PDV7M{i=
MM.1S	MWLDfZRwfG:6aXPpeJkhSXO\|YYm=	MlnEPVAhyrWP	M2\mRVEhcA>?		NV7YS\|BX[myxY3vzJGJCYSBzMT23NFgzKGmwZIXj[YQhemGyaXSgZ4VtdCC\|d3XscIlv\w>?	NIfk[\|MzOzV{N{G1OC=>
KMS-12-BM	M2GyPGN6fG:2b4jpZ4l1gSCDc4PhfS=>	M{W1SFkxKML3TR?=	M1HYV\|EhcA>?		MlPQZoxw[2u\|IFLBXUAyOS15MEiyJIlv\HWlZXSgdoFxcWRiY3XscEB{f2WubHnu[y=>	MkK3NlM2OjdzNUS=
HT-22	NXewZW0zS2WubDDWbYFjcWyrdImgRZN{[Xl?	M3LkfFExyqEQvF2=	M4\sTlEzyqCq	MX;EUXNQ	NVjxO\|ZieHKxdHXjeJMh[WejaX7zeEBodHW2YX3heIUucW6mdXPl[EBk\WyuIHTlZZRp	MUWyN\|MxPzd3Mh?=
HT-22	NF;aSlJHfW6ldHnvckBCe3OjeR?=	MXGyOeKh\|ryP	NWnzfXJ1OOLCk{OwxsBucW5?	M4PtWWROW09?	MY\pcohq[mm2czDFVmshSWO2aY\heIlwdiCrbnT1Z4VlKGK7IHfseZRidWG2ZR?=	Mn33NlM{ODd5NUK=
NIH3T3	M2fBZWZ2dmO2aX;uJGF{e2G7	Mo\SNVAwPTBizszN	NYX0c45OOS9\|IHi=		MkS5ZY1mdGmxcnH0[ZMhXE6IzsGt[JJqfmWwIHPvcZBt\XhiZn;ycYF1cW:w	NUPUcZpCOjN{NkG2O\|c>
SH-EP	MkPpRZBweHSxc3nzJGF{e2G7	M4\sbVEx6oDLzszNxsA>	NXjWeG57PzMkgJnoxsA>		MYnpcohq[mm2czDJRXAhcW6qaXLpeI9zNSCjbnSgUIV5[XS3bYXtZYIucW6mdXPl[EBieG:ydH;zbZM>	MUCyNlg6ODN{Mh?=
HL60	MUPBdI9xfG:\|aYOgRZN{[Xl?	NFO5[HI3OCEQvF2=	MVyxNkBp		NWjjd4Fs\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM>	MWeyNlg{PzZ6OR?=
HL60/Adr	NUL2dVJpSXCxcITvd4l{KEG\|c3H5	MVO2NEDPxE1?	MmjDNVIhcA>?		MmPP[Y5p[W6lZYOgd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:\|aYO=	M2fpTlIzQDN5Nki5
K562	MXfBdI9xfG:\|aYOgRZN{[Xl?	MVy2NEDPxE1?	NVPSNlFqOTJiaB?=		NVrKfIJC\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM>	MVKyNlg{PzZ6OR?=
K562/Adr	NFf5fFlCeG:ydH;zbZMhSXO\|YYm=	Mn3XOlAh\|ryP	M4DpOFEzKGh?		NHnCZ5RmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MYGyNlg{PzZ6OR?=
HL60	MnrYSpVv[3Srb36gRZN{[Xl?	M{HLUlYxKM7:TR?=	MWmxNkBp		MWjheYdu\W62czD0bIUh[2G\|cHHz[U0{KGGldHn2bZR6	MVSyNlg{PzZ6OR?=
HL60/Adr	MlPlSpVv[3Srb36gRZN{[Xl?	NH\td2I3OCEQvF2=	MlPRNVIhcA>?		MVzheYdu\W62czD0bIUh[2G\|cHHz[U0{KGGldHn2bZR6	MoW0NlI5Ozd4OEm=
K562	M2CwUmZ2dmO2aX;uJGF{e2G7	Mn35OlAh\|ryP	NGjGSIwyOiCq		NYrHfnlr[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?=	MX:yNlg{PzZ6OR?=
K562/Adr	M13wd2Z2dmO2aX;uJGF{e2G7	NUP4XpFxPjBizszN	MVGxNkBp		M4iwcYF2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl?	Ml6yNlI5Ozd4OEm=
HL60	MYDGeY5kfGmxbjDBd5NigQ>?	NF3GUVA3OCEQvF2=	M{PJUlEzKGh?		NISzbWhqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm=	NEjuPFczOjh\|N{[4PS=>
HL60/Adr	NFiyRW5HfW6ldHnvckBCe3OjeR?=	MnzuOlAh\|ryP	M3zYR\|EzKGh?		NYXOTpRYcW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G\|cHHz[UA5KGGwZDC5	M2PBN\|IzQDN5Nki5
K562	NXTmSFMzTnWwY4Tpc44hSXO\|YYm=	MnfNOlAh\|ryP	NEXJNmUyOiCq		M1[0folv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG\|ZYOsJINie3Cjc3WgPEBidmRiOR?=	M1zrc\|IzQDN5Nki5
K562/Adr	MWXGeY5kfGmxbjDBd5NigQ>?	MWC2NEDPxE1?	M2PwU\|EzKGh?		M{\6Zolv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG\|ZYOsJINie3Cjc3WgPEBidmRiOR?=	M2ThO\|IzQDN5Nki5
L929sA	M1vHTWFxd3C2b4Ppd{BCe3OjeR?=	NFfrZWcyOCEQvF2=	Moe5NUBp		MmPobY5pcWKrdIOgeIhmKGGyb4D0c5Rq[yC{ZYPwc45{\SC2bzDUUmY>	M3nWVlIzOzZ{N{[3
L929sA	MWnBdI9xfG:\|aYOgRZN{[Xl?	MX6xNEDPxE1?	Mn7xNUBp		NV6xe3l5emW\|Y4Xld{Bk\WyuczDlfJBz\XO\|aX7nJHJKWEtzzqTJSEBnem:vIGTOSk1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MmCyNlI{PjJ5Nke=
L929sA	MVLBdI9xfG:\|aYOgRZN{[Xl?	M4fIPFExKM7:TR?=	MXuxJIg>		MmnPZYJzd2ejdHXzJJRp\SCrboTldoFkfGmxbjDv[kBk[XOyYYPlMVghf2m2aDDGRWRF	M374cVIzOzZ{N{[3
TPC-1	NFjCcFdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVyxNFAh\|ryP	NX7pR253OjRiaB?=	MU\EUXNQ	M3TwdIlv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=>	Mne5NlIyOzZ6MUi=
8505c	NVXyZ49GS2WubDDWbYFjcWyrdImgRZN{[Xl?	Ml7UNVAxKM7:TR?=	M1HNVFI1KGh?	M4rVfmROW09?	MX3pcoNz\WG\|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy=	M3jrbFIzOTN4OEG4
SW13	NHzTTGdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Ml\UNVAxKM7:TR?=	NFvqb\|kzPCCq	MULEUXNQ	NWKy[IxwcW6lcnXhd4V{KGOnbHz1cIFzKHO3co\peoFt	NEPaT2MzOjF\|NkixPC=>
Jurkat	M3jxXGN6fG:2b4jpZ4l1gSCDc4PhfS=>	NXKzbHNmPTBxIEGwNE8zODEEoN88cS=>	MUGxM\|MhcA>?		NFW5b4Vz\WS3Y3XzxsBP[WWpbHXybYEh\m:5bHXybU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	Ml24NlE2OzVyMkC=
Jurkat	MYTGeY5kfGmxbjDBd5NigQ>?	M{PwRVIxOMLizszt	MUmzNEBucW5?		NV[5[IF[emWmdXPld:KhVmGnZ3zldoliKG[xd3zldokucW6mdXPl[EBz\WGldHn2[UBwgHmpZX6gd5Bm[2mnczCoVm9UMSCpZX7ldoF1cW:w	NH;pZ5MzOTV\|NUCyNC=>
HT-22	M2mwW2N6fG:2b4jpZ4l1gSCDc4PhfS=>	NGewV3IyOCEQvF2=	MXuxNkBp		NInYOo9xem:2ZXP0d{Bi\2GrboP0JINmdGxiZHXheIghcW6mdXPl[EBjgSB3wrDtcY9tN0xiZ3z1eIFu[XSnwrC=	MWWxO\|c3ODh4OR?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Immunofluorescence	RIP1 / RIP3 ; PubMed: 30462730 PLoS One Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.	30462730

Protocol

Kinase Assay:

^[1]

- Collapse

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-³²P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.

Cell Research:

^[2]

- Collapse

Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
Concentrations: 0.01-100 μM
Incubation Time: --
Method:
Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC₆ for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.

(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	51 mg/mL warmed (196.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Necrostatin-1 SDF

Molecular Weight	259.33
Formula	C₁₃H₁₃N₃OS
CAS No.	4311-88-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN1C(=O)C(CC2=C[NH]C3=CC=CC=C23)NC1=S

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

TNF-alpha Signaling Pathway Map

Related TNF-alpha Products

MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
Lenalidomide (CC-5013)

Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.
Thalidomide

Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.
Pomalidomide

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.

Features:A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
Z-VAD-FMK

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Features:A key compound for apoptosis studies.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Necrostatin-1